Condition: Cesarean Delivery Affecting Newborn · Obesity, Childhood · Intestinal Microbiome · Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Neonates delivered by scheduled Cesarean Section will be randomized to receive vaginal seeding (exposing the infant to Mother's vaginal flora) or sham. Infants will be followed for three years to examine health outcomes including microbiome development, immune development, metabolic outcomes, and any adverse events.
This description comes directly from the study's public registry record.
Suchitra Hourigan, MD · 703-776-8489 · suchitra.hourigan@inova.org, suchitra.hourigan@nih.gov
Shira Levy · 703-776-8489 · shira.levy@inova.org
Always discuss trial participation with your own doctor first.
| Inova Health System | Falls Church, Virginia, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03298334